Gene Cell Tissue. 2025 January; 12(1): e156864 https://doi.org/10.5812/gct-156864

Published Online: 2024 November 20 **Letter**

Enhancing Maxillofacial Development: The Role of Genetic Modifications

Mehrdad Shahraki [1], Amir Hossein Khazaei [2], Sadra Amirpour Haradasht [1,*]

[1] Department of Oral and Maxillofacial Surgery, School of Dentistry, Zahedan University of Medical Sciences, Zahedan, Iran
[2] Oral and Dental Disease Research Center, Faculty of Dentistry, Zahedan University of Medical Sciences, Zahedan, Iran

[*] ***Corresponding Author:*** Department of Oral and Maxillofacial Surgery, School of Dentistry, Zahedan University of Medical Sciences, Zahedan, Iran. Email: sadraharadasht@gmail.com

Received: 6 October, 2024; **Revised:** 23 October, 2024; **Accepted:** 26 October, 2024

Keywords: Maxillofacial, Genetic, Genetic Variation, Enhancing

Dear Editor,

Maxillofacial development involves the growth and formation of the craniofacial region, including the jaw, facial bones, and surrounding soft tissues. Abnormalities in this area can cause considerable functional and aesthetic issues, affecting speech, chewing, and overall quality of life. Traditional treatments for maxillofacial deformities include surgical procedures and orthodontic interventions. However, with advances in genetic modification techniques, there is potential for more precise and effective therapies that could improve or correct developmental pathways (1).

Materials and Methods

In this study, we focused on the application of genetic modification techniques, specifically CRISPR-Cas9, to enhance maxillofacial development. The review utilized keywords such as "genetic," "genetic variation," "maxillofacial," and "enhancing." Relevant articles in English were selected from databases including Google Scholar, Science Direct, PubMed, and ResearchGate.

Genetic Basis of Maxillofacial Development

The maxillofacial region, encompassing the jaw, facial bones, and associated soft tissues, undergoes complex developmental processes regulated by an intricate network of genetic factors. Abnormalities in this area can lead to significant functional and aesthetic challenges, highlighting the importance of a thorough understanding of the underlying genetics. Advances in molecular genetics have provided critical insights into the genes that control craniofacial development, enabling the exploration of innovative therapeutic strategies. Key genes, including Msh Homeobox 1 (MSX1), fibroblast growth factor receptor 2 (FGFR2), and snail family zinc finger 2 (SNAI2), play essential roles in craniofacial formation, regulating processes such as cell proliferation, differentiation, and migration. Mutations or dysregulations in these genes can lead to congenital defects, such as cleft lip and palate, craniosynostosis, and other anomalies (2, 3).

(1) MSX1

The MSX1 gene is a homeobox gene essential for craniofacial development. It plays a critical role in the patterning and growth of facial structures. Mutations in MSX1 have been associated with conditions such as cleft lip and palate, underscoring its importance in normal developmental processes.

(2) FGFR2

Fibroblast growth factor receptor 2 is essential for bone development and cellular signaling during embryogenesis. Alterations in FGFR2 are associated with craniosynostosis syndromes, characterized by the premature fusion of cranial sutures. This highlights the gene's pivotal role in regulating craniofacial morphogenesis.

(3) SNAI2

Snail family zinc finger 2 plays a critical role in epithelial-mesenchymal transition (EMT), a process essential for the migration of neural crest cells during craniofacial development. Disruptions in SNAI2 can lead to severe craniofacial anomalies, underscoring its significance in the developmental pathway.

(4) SOX9 (SRY-Box Transcription Factor 9)

SRY-Box Transcription Factor 9 is a transcription factor essential for chondrogenesis and the development of various skeletal elements in the face.

Mutations in SOX9 are associated with disorders such as Campomelic dysplasia, which is marked by severe craniofacial deformities.

(5) WNT Signaling Pathway

The WNT signaling pathway, encompassing numerous genes, is crucial for regulating cell proliferation and differentiation during craniofacial development. Dysregulation of this pathway has been associated with various craniofacial malformations, underscoring its fundamental role in the developmental process (3-6).

Genetic Modification Techniques

CRISPR-Cas9 is a groundbreaking genome-editing tool originating from the adaptive immune system of bacteria. It comprises two primary components: (1) the Cas9 nuclease, which creates double-strand breaks in DNA, and (2) a guide RNA (gRNA) that directs Cas9 to specific genomic sequences. The precision of CRISPR-Cas9 enables researchers to add, delete, or modify genes with high specificity, making it a powerful tool for developing targeted therapies for genetic conditions (7).

Mechanism of Action

(1) Design of gRNA: Researchers design a gRNA that is complementary to the target DNA sequence.

(2) Formation of the Cas9-gRNA Complex: The gRNA binds to Cas9, forming a ribonucleoprotein complex.

(3) Targeting and Cleavage: The complex locates the target DNA sequence in the genome, where Cas9 creates a double-strand break.

(4) DNA Repair: The cell's natural repair mechanisms, either non-homologous end joining (NHEJ) or homology-directed repair (HDR), repair the DNA break, enabling precise modifications (7, 8).

Applications in The Maxillofacial Area

(1) Correction of Genetic Disorders

CRISPR-Cas9 has the potential to correct genetic mutations responsible for craniofacial abnormalities, such as cleft lip and palate. By targeting and repairing specific mutations in genes like MSX1 or FGFR2, researchers aim to restore normal developmental pathways.

(2) Tissue Regeneration and Engineering

The ability to edit genes involved in cellular differentiation and proliferation can enhance tissue engineering efforts in the maxillofacial area. For example, modifying stem cells to promote chondrogenesis could lead to improved outcomes in reconstructive surgery, particularly for patients with congenital defects or trauma.

(3) Enhancing Bone Healing

CRISPR technology can be applied to modify genes related to bone healing and regeneration. By targeting pathways associated with osteogenesis, such as the WNT signaling pathway, CRISPR-Cas9 may enable faster and more effective bone repair after surgery.

(4) Cancer Research

In cases of oral cancers, CRISPR-Cas9 can be used to study the genetic alterations that drive tumorigenesis. Understanding these changes can contribute to the development of targeted therapies that improve patient prognosis and treatment outcomes.

The future of CRISPR-Cas9 in maxillofacial applications is promising, with ongoing research dedicated to enhancing the precision and efficiency of this technology. Advances like base editing and prime editing may provide even greater control over genetic modifications, reducing off-target effects and broadening the spectrum of treatable conditions.

Alongside CRISPR, other genetic tools such as TALENs (Transcription activator-like effector nucleases) and ZFNs (zinc finger nucleases) offer additional methods for modifying genes involved in craniofacial development. These technologies present alternative strategies with varying levels of efficiency and specificity.

A particularly exciting application of genetic modification is the correction of congenital maxillofacial deformities. By targeting specific genetic mutations, it may become possible to prevent conditions like cleft lip and palate during embryonic development, reducing the need for extensive surgical interventions later in life (7, 9, 10).

Genetic modification also holds substantial potential in regenerative medicine. For instance, stem cells derived from patients could be genetically modified to enhance their regenerative capacity for maxillofacial tissues. This approach could lead to improved outcomes in reconstructive surgeries and trauma recovery (10).

The future of maxillofacial surgery may increasingly rely on personalized medicine, where genetic profiles inform treatment plans. By understanding an individual's genetic predispositions, clinicians can tailor interventions to optimize developmental outcomes and minimize complications. While the potential benefits of genetic modifications in maxillofacial development are substantial, ethical concerns must also be addressed. Issues such as gene editing in embryos, the potential for unintended consequences, and the social implications of "designer" traits pose significant challenges. Additionally, regulatory frameworks must evolve to ensure that

genetic modifications are carried out safely and responsibly.

Enhancing maxillofacial development through genetic modifications represents a frontier in both genetics and clinical practice. As research advances and technologies continue to progress, there is optimism for innovative solutions to long-standing challenges in maxillofacial surgery. However, it is crucial to thoughtfully navigate the ethical landscape to harness these technologies for patient benefit while safeguarding against potential misuse (1, 6).

Footnotes

Authors' Contribution: This Study was designed by M. S. and S. S.; while acquisition of data and analysis and interpretation of data was done by K. K. and M. S. in a cooperating proses. Drafting the manuscript was done by S. S. and he had the responsibility to supervise the study.

Conflict of Interests Statement: The authors have no conflict of interest to declare.

Funding/Support: The authors declared no funding.

References

1. Antonelli A, Bennardo F, Giudice A. Breakthroughs in Oral and Maxillofacial Surgery. *J Clin Med*. 2024;**13**(3). [PubMed ID: 38337379]. [PubMed Central ID: PMC10856085]. https://doi.org/10.3390/jcm13030685.
2. Ahmed MK, Ye X, Taub PJ. Review of the Genetic Basis of Jaw Malformations. *J Pediatr Genet*. 2016;**5**(4):209-19. [PubMed ID: 27895973]. [PubMed Central ID: PMC5123890]. https://doi.org/10.1055/s-0036-1593505.
3. Neela PK, Atteeri A, Mamillapalli PK, Sesham VM, Keesara S, Chandra J, et al. Genetics of Dentofacial and Orthodontic Abnormalities. *Glob Med Genet*. 2020;**7**(4):95-100. [PubMed ID: 33693441]. [PubMed Central ID: PMC7938796]. https://doi.org/10.1055/s-0040-1722303.
4. Lidral AC, Reising BC. The role of MSX1 in human tooth agenesis. *J Dent Res*. 2002;**81**(4):274-8. [PubMed ID: 12097313]. [PubMed Central ID: PMC2731714]. https://doi.org/10.1177/154405910208100410.
5. Morice A, Cornette R, Giudice A, Collet C, Paternoster G, Arnaud E, et al. Early mandibular morphological differences in patients with FGFR2 and FGFR3-related syndromic craniosynostoses: A 3D comparative study. *Bone*. 2020;**141**:115600. [PubMed ID: 32822871]. https://doi.org/10.1016/j.bone.2020.115600.
6. Salerno C, D'Avola V, Oberti L, Almonte E, Bazzini EM, Tartaglia GM, et al. Rare Genetic Syndromes and Oral Anomalies: A Review of the Literature and Case Series with a New Classification Proposal. *Children (Basel)*. 2021;**9**(1). [PubMed ID: 35053637]. [PubMed Central ID: PMC8774676]. https://doi.org/10.3390/children9010012.
7. S VS, Augustine D, Mushtaq S, Baeshen HA, Ashi H, Hassan RN, et al. Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing. *Front Oncol*. 2024;**14**:1383062. [PubMed ID: 38915370]. [PubMed Central ID: PMC11194394]. https://doi.org/10.3389/fonc.2024.1383062.
8. Chavez-Granados PA, Manisekaran R, Acosta-Torres LS, Garcia-Contreras R. CRISPR/Cas gene-editing technology and its advances in dentistry. *Biochimie*. 2022;**194**:96-107. [PubMed ID: 34974144]. https://doi.org/10.1016/j.biochi.2021.12.012.
9. Lee MH, Shin JI, Yang JW, Lee KH, Cha DH, Hong JB, et al. Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review. *Int J Mol Sci*. 2022;**23**(3). [PubMed ID: 35163260]. [PubMed Central ID: PMC8835887]. https://doi.org/10.3390/ijms23031337.
10. Melek LN. Tissue engineering in oral and maxillofacial reconstruction. *Tanta Dental Journal*. 2015;**12**(3):211-23. https://doi.org/10.1016/j.tdj.2015.05.003.